Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Inclusion Criteria: * Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary. * Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer (defined as progressing while on a platinum-based chemotherapy) * At least treated with one line of platinum-based chemotherapy * Female, age ≥18 years and ≤70 years, signed informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version * Patients must have a life expectancy of at least 3 months. * Patients must have adequate organ function as defined by the following criteria: * White blood cell count ≥ 3 x 10\^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x 10\^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10\^9/L * Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN * Serum creatinine ≤ 1 x ULN Exclusion Criteria: * Had prior exposure to apatinib or has known allegies to any of the excipients. * History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1. * Patients with QT interval prolongation * Serious, non-healing wound, active ulcer, bowel obstruction. * History of abdominal fistula or gastrointestinal perforation within 28 days prior to Day 1 * Evidence of bleedi…